Consti reports its Q3/24 results on Friday 25th of October.
Q3 due Thursday, 24 October, 07:00 CET We expect improved orders on pent-up demand and light comps W...
Redeye updates on EG7 ahead of Q3-results (due 12 Nov) where we see potential for sequential improve...
Redeye comments on Thunderful Group ahead of its Q3 results, due on November 14.
Redeye updates its estimates and valuation following Safeture’s Q3 2024 report.
Redeye comments on the announcement of the achievement of a significant milestone as AMA Issues Perm...
Redeye makes negligible estimate revisions on the back of I-Tech’s Q3 report, which posted continued...
Elanders presented a solid Q3 2024 report with 4% y/y organic sales growth, primarily due to the str...
Q3 weaker than expected... ...but overall outlook is intact Well positioned for market recovery Enc...
Q3: Sales SEK 41m, +27% y-o-y, adj. EBIT margin 27% (25%) Raise '24e-'26e sales and EBIT adj.
Sales temporarily weaker (down 4%), but record gross margin of 47% We cut '24e-'26e sales by 4-5% an...
Plejds nettoomsättning för det tredje kvartalet 2024 uppgick till 153,1 MSEK (119,9), en ökning med ...
Redeye comments on Annexin's Q3 report and recent events in the company, most notably the top-line d...
Finnair reports Q3 results on Oct 29. The market still isn’t too bad for Finnair should jet fuel pri...
19% ARR growth and 19% EBITDA margin, guidance raised again '25 guidance: ~13% ARR growth and 18-20%...
Redeye states that Q3 numbers aligned well with our expectations.
Sales -12% and adj. EBIT SEK -4m vs. ABGSCe Lower volumes from some large customers likely temporary...
Sales +5% and EBIT adj. +3% vs. ABGSCe Strong momentum in Selektope sales Diversified customer base ...
Q3: EBITDA of NOK 12m vs. our NOK 10m, on lower costs Still relatively low visibility Estimates like...
Hansa delivers a healthy increase in patients using IDEFIRIX.
